The chart above explains what I mean. Keryx shares (the blue line) are down almost 13% since the start of February while the Nasdaq Biotechnology Index (NBI in orange) is up more than 23%.
I used the beginning of February as the meaningful starting point to track Keryx's performance on purpose to exclude the upward spike in the stock's value on Jan. 28. That's the day Keryx released positive results from the long-term, phase III study of its kidney dialysis phosphate binder Zerenex. Over four trading days starting Jan. 28 through Jan. 31, Keryx's stock almost tripled in value -- a reaction biotech investors are accustomed to seeing on positive clinical trial results.Since that four-day burst of buying activity, the value of Keryx shares is down 13%. Odd, particularly in the raging biotech bull market where even low-quality stocks are moving higher. Keryx is still up more than 200% year to date, so I don't mean to suggest the stock is a total laggard. Just noting that after the initial buying surge in late January caused by the Zerenex data, investors have been avoiding the stock. Why? A lot of factors might be working against Keryx but my best guess is investors lack confidence in the patent protection and market exclusivity for Zerenex. If Keryx has trouble defending its Zerenex patents and/or fails to obtain five years of market exclusivity as a New Chemical Entity (NCE) from the FDA, a Big Pharma partner or acquirer isn't likely to materialize. Investors aren't thrilled with the idea of Keryx selling Zerenex on its own, hence the stock's underperformance for most of this year. In short, Keryx equals Amarin (AMRN). I'm not going to replay the bull-bear argument over Zerenex's patents and NCE status here. Keryx and its supporters believe the Zerenex patents are enforceable and Big Pharma interest in the new phosphate binder will be significant. Investors shorting Keryx believe otherwise. Judging by the stock's performance this year, I'd say Keryx has more work to do clearing up worries about Zerenex's patents and potential for market exclusivity. One more chart to look at. This one (on the next page) tracks the performance of Acadia Pharmaceuticals (ACAD) since the end of November 2012, after the release of positive results from the phase III study of pimavanserin in Parkinson's psychosis.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV